Royalty Report: Drugs, HIV / AIDs, Antibody – Collection: 243414

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Drugs
  • HIV / AIDs
  • Antibody
  • Cancer
  • Disease
  • Pharmaceuticals
  • Drug Discovery
  • cell therapy
  • Viral Infection
  • Therapeutic
  • Drug Testing
  • Proteins
  • Vaccine

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 243414

License Grant
Licensor grants an exclusive license under the Technology and Patents to make, have made, import, use, offer for sale, and sell Licensed Product for use in the Field.  The license granted shall include the right to grant a sublicense to one Sublicensee in each country.
License Property
Licensor owns certain patent rights and technology relating to Anti-CD4 Monoclonal Antibodies.
Field of Use
The field shall mean the manufacture, use, importation, offer for sale or sale of Licensed Product for human use only, including therapeutic, prophylactic and diagnostic use.

5A8 is a humanized anti-CD4 monoclonal antibody that is in preclinical development for treatment of human immunodeficiency virus, or HIV. The virus enters the host cell by binding to the CD4 receptors on these cells. In lab studies, our 5A8 antibody binds to the CD4 receptor on the cell surface and prevents viral entry into the cell, thereby blocking infection.

IPSCIO Record ID: 322463

License Grant
Licensor sold Leronlimab to Licensee where Licensee is responsible for all development, manufacturing and commercialization efforts.
License Property
Leronlimab (PRO 140) is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases including certain liver diseases.

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells.

In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control.  Blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer.

Field of Use
The field of use is for the treatment in HIV infection, tumor metastases, and other diseases including certain liver diseases.

HIV (human immunodeficiency virus) is a virus that attacks cells that help the body fight infection.
Metastasis means that cancer spreads to a different body part from where it started.
Liver cancer is the growth and spread of unhealthy cells in the liver.

Licensee is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.

IPSCIO Record ID: 289819

License Grant
Licensor hereby grants to Licensee an exclusive royalty-bearing license (or sublicense, as the case may be), under the Licensor Patents, the Licensor  Know-How and the Inventions (if any) solely to Commercialize, use, have used, offer for sale and sell Licensed Products in the Field in the Territory.

With this agreement, Licensor will maintain responsibility for the development and FDA approval of leronlimab for all HIV-related and other indications, while Licensee has been granted an exclusive license to market and distribute leronlimab.

License Property
Leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells.

Licensor has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (“HIV”) infection, as well as related HIV infection indications.

Field of Use
The field of use is for the treatment of HIV.

IPSCIO Record ID: 336294

License Grant
Licensor hereby grants to Japanese Licensee and its Affiliates the exclusive (even as to Licensor) right and license (with the right to sublicense upon prior written notice to Licensor, except that sublicensing of manufacturing rights shall require Licensors prior written approval, which approval shall not unreasonably be withheld) within the Field of Use and in the Territory under the Licensor Patent Rights and Licensor Know How to manufacture, use and sell Anti-CD4 Antibodies under Licensees trademarks or trade names, subject to the obligation to pay royalties to Licensor in accordance with Article V.

In case Licensee exercises the right to manufacture Anti-CD4 Antibodies, Licensee shall give Licensor at least eighteen (18) months prior written notice of its intention to exercise such right.

License Property
Anti-CD4 Antibodies shall mean human anti-CD4 monoclonal antibodies produced from Transgenic Mice (as hereinafter defined) and developed in the course of the Research Program (as hereinafter defined).

The Licensor is developing MDX-CD4, a HuMAb-Mouse fully human antibody, for the treatment of rheumatoid arthritis and other autoimmune disorders. MDX-CD4 binds to human CD4, which is present on the surface of certain T-cells in the human immune system. By binding to such T-cells, MDX-CD4 is designed to inactivate or reduce the ability of these cells to mediate the persistent inflammation characteristics of such autoimmune diseases. The Licensor commenced Phase I clinical trials of MDX-CD4 in 1998.

Field of Use
Field of Use shall mean the use of Anti-CD4 Antibodies in human therapy. If expanded in accordance with this Agreement, Field of Use shall also include the use of Anti-CD4 Antibodies in human diagnostics.

IPSCIO Record ID: 203504

License Grant
Licensor grants an exclusive (even as to  Licensor), license under the Patent Assets and Know-How, including the right to grant sublicenses, to develop, make, have made, use, import, offer for sale, market and sell and otherwise dispose of Compound and Product, including any Improvements thereto, in the Territory.
License Property
The Licensed products contain the compound.  The Compound shall mean a condensation polymer of an aromatic sulfonic acid and an aldehyde or a pharmaceutically acceptable salt or prodrug thereof or a derivative, homolog, or analog thereof.
Field of Use
The Compound is for a candidate topical microbicide used to prevent infection by the human immunodeficiency virus (HIV) and other sexually transmitted pathogens.

IPSCIO Record ID: 243415

License Grant
Licensor grants the Licensees of Switzerland and the United States, a worldwide, sole and exclusive right and license, with the right to sublicense, to make and have made, use, offer for sale, import and sell Compounds and Products under the Licensor Proprietary Rights and Licensors part of the Joint Patents.
License Property
Licensor has discovered and is developing a series of proprietary compounds which act by binding to the glycoprotein GP 41 of the Human Immunodeficiency virus.

Compound 1 shall mean T-20.
Compound 2 shall mean T-1249, or its Replacement Compound

Licensor discovers and develops novel therapeutic agents that block viral infection by inhibiting viral fusion with host cells.

Field of Use
The Field of Use shall mean the treatment of HIV, a human viral infection.

IPSCIO Record ID: 26363

License Grant
The Company entered into a worldwide exclusive patent license agreement with the Licensor, government public health organization, concerning composition of matter for BlockAide/CR.
License Property
BlockAide/CR&#-3884; is a peptide-based drug that is intended to work by blocking viral entry and infection of human immune system cells.

The patents covering a peptide product, known as BlockAide, for the treatment and prevention of HIV.

Field of Use
The rights granted apply to the medical industry relating to human infections.

IPSCIO Record ID: 369249

License Grant
Licensor grants an exclusive, worldwide, license, with the right to sublicense, under the Licensor Technology to research, develop, make, have made, use, sell, offer for sale and import Licensed Products solely in the Antibody Targeting Technology Field.

Licensor grants an exclusive, worldwide, license, with the right to sublicense, under the HuMAb Technology and the Licensor Technology to research, develop, make, have made, use, sell, offer for sale and import
— Licensed Royalty-Bearing Products solely in the Antibody Targeting Technology Field, and,
— Anti-Mannose Products.

For Hybridoma Cell Lines; Research License, Licensor grants an exclusive, worldwide license, with the right to sublicense, under the HuMAb Technology to research, make, have made, transfer physical possession of, but not to sell, lease, offer to sell or lease, or otherwise transfer title to, the Hybridoma Cell Lines.

Licensor grants a non-exclusive, worldwide, license, with the right to sublicense, under the Research Patent to conduct research.

For Research Antibodies License, Licensor grants an exclusive, worldwide license, without the right to sublicense, under the HuMAb Technology and the Licensor Technology to use the Research Antibodies for the sole purpose of determining the antigen with respect to which each Research Antibody was raised.

Licensor, who has incorporated Licensee for business opportunities outside of Licensors core business, irrevocably, perpetually and forever assigns and conveys Licensors entire right, title and interest in and to each of the following Assigned Assets
— Antibody Targeting Patents;
— Antibody Targeting Know-How;
— Anti-Mannose Receptor HuMAb Antibodies;
— the Investigational New Drug Application # 11,508 and related governmental filings, and the right to make any future or foreign related filing on –X-1307;
— all quantities of Biological Materials, including those in the possession or control of counterparties to Assigned Contracts;
— all clinical inventories of –X-1307 in the possession or control of Licensor as of the Effective Date; and
— the agreements that are Assigned Contracts.

License Property
Licensor owns or otherwise controls certain technology, including certain patents and know-how, relating to the use of antibodies in connection with the research and development of vaccines.

Anti-Mannose Product shall mean any pharmaceutical composition or formulation incorporating an Anti-Mannose Receptor HuMAb Antibody.

HuMAb Mouse® shall mean any of Licensors immunizable transgenic mice containing unrearranged human immunoglobulin heavy and light chain transgenes, each inserted into mouse chromosomes, but excluding the Additional Mice. HuMAb Mice® shall mean more than one HuMAb Mouse.

The patents relate to Anti-FcyRI (CD64) antibodies.

Field of Use
The field of use is the Antibody Targeting Technology Field.  The Antibody Targeting Technology Field shall mean the use of an antibody, or fragment thereof, whereby the antibody or fragment serves as a targeting means with respect to an Antigen-Presenting Cell for the purpose of modulating an immune response in any of the following manners
—  an antibody or fragment chemically attached or genetically fused to an antigen (including an antigen that is an antibody, or fragment thereof, that encodes an idiotype antigen), whereby the antibody, or fragment thereof, serves as a targeting means for delivering such antigen to an Antigen-Presenting Cell for the purpose of eliciting an immune response,
— an antibody or fragment chemically attached or genetically fused to a toxin or radionuclide, whereby the antibody, or fragment thereof, serves as a targeting means for delivering such toxin or radionuclide to an Antigen-Presenting Cell for the purpose of decreasing, down-regulating or eliminating the activity of such Antigen-Presenting Cell,
— an antibody or fragment chemically attached or genetically fused to a cytokine, adjuvant, or other immuno-modulatory compound, whereby the antibody, or fragment thereof, serves as a targeting means for delivering such compound to an Antigen-Presenting Cell for the purpose of modulating the activity of such Antigen-Presenting Cell, and
— an antibody, or fragment thereof, alone, whereby the antibody or fragment binds to a particular antigen on the surface of an Antigen-Presenting Cell and through such binding modulates the activity of such Antigen-Presenting Cell.

IPSCIO Record ID: 25977

License Grant
The Canadian Licensor will grant the Licensee an exclusive sub-license option on technology to use the technology in Licensor's antibody improvement platforms. The technology grant will also include the non-exclusive use to make genetically engineered forms or humanized forms and to derive fully human antibodies.
Field of Use
Licensee will use best efforts to promptly commercialize the technology as permitted in this SubLicense.

IPSCIO Record ID: 109479

License Grant
Pursuant to this agreement, to use the Mice to evaluate their utility for the development of fully human monoclonal antibodies to the human CRl complement receptor (CRl) and Staphylococcus aureus, Licensee has the right to exercise an option for a commercial license where Licensor shall grant the following licenses
(a) an exclusive, worldwide, non-transferable license under the Licensors Technology to use the Mice to make Antibodies, and
(b) an exclusive, worldwide license under the Licensors Technology, with the right to sublicense, to use such Antibodies to make, have made, import, have imported, use, offer for sale and sell Products.
License Property
Licensor is the sole and exclusive owner of certain transgenic Mice useful for the preparation of fully human monoclonal antibodies.

Antibody means a human monoclonal antibody with binding affinity for an Antigen derived by Licensee or its Affiliates or Sublicensees from cells obtained from one or more of the Mice.

Product shall mean any product for the treatment of human disease containing an Antibody with affinity for CRI, or a bispecific antibody consisting of a combination of an Antibody with affinity for CRI and an Antibody to Staphylococcus aureus.

'Mice' shall mean immunizable sterile transgenic mice containing unrearranged human immunoglobulin genes.

Field of Use
This agreement is for the biotechnology industry.  Licensee wishes to acquire from Medarex an option to acquire a commercial license for the use of such monoclonal antibodies to commercialize Products.

IPSCIO Record ID: 362455

License Grant
The University grants an exclusive, worldwide, right and license under the University Subject Technology to develop, make, have made, use, market, import, have imported, Sell, offer for Sale and have Sold any and all Licensed Products in the field and in the Territory.
License Property
The University owns certain intellectual property relating to the treatment of Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV).

Licensed Products means a product containing P-VL-FD4C that is developed, made, used, marketed, imported, Sold, or offered for Sale by Licensee, its Affiliates or any Sublicensees in any country of the Territory where the University owns or controls at least one Valid Claim covering the Subject Technology.

University Subject Technology shall mean all technology, trade secrets, know-how, methods of treatment, documents, materials, tests, all improvements thereto, and all proprietary information pertaining to the compound B-L-FD4C (2 ,3-dideoxy-2 ,3 -didehydro-B-L-5-fluorocytidine) or any 5- or N4 derivatives or products thereof.

Field of Use
Field means all human prophylactic and therapeutic applications with respect to HIV and HBV.

IPSCIO Record ID: 361677

License Grant
Licensor assigned to Licensee in the Progenics Purchase Agreement, pursuant to which we have an exclusive worldwide license to develop, make, have made, import, use, sell, offer to sell or have sold products that incorporate the humanized form of the leronlimab antibody developed under the agreement.
License Property
Leronlimab, a monoclonal antibody C—C chemokine receptor type 5 (“CCR5”) receptor antagonist, to be used as a platform drug for various indications. The target of leronlimab is the immunologic receptor CCR5. The CCR5 receptor is a protein located on the surface of various cells including white blood cells and cancer cells. On white blood cells, it serves as a receptor for chemical attractants called chemokines. The CCR5 receptor is also the co-receptor needed for certain strains of HIV to infect healthy T-cells. Recent research has identified the CCR5 receptor as an important target for many disease processes, including cancer metastasis and certain immunological conditions. Leronlimab is a unique humanized monoclonal antibody.

Leronlimab binds to the second extracellular loop and N-terminus of the CCR5 receptor, and due to its selectivity and target-specific mechanism of action, leronlimab does not appear to activate the immune function of the CCR5 receptor through agonist activity. This apparent target specificity differentiates leronlimab from other CCR5 antagonists. Leronlimab is a competitive rather than allosteric inhibitor of the CCR5 receptor.

Field of Use
Leronlimab (PRO 140) is a CCR5 antagonist with the potential for multiple therapeutic indications, today provided an update on leronlimab (PRO140) as a single agent for maintenance of HIV viral load suppression (HIV-1 RNA < 50 copies/mL).

The latest investigative monotherapy trial has revealed sufficient data to more precisely design the pivotal Phase 3 monotherapy trial that Licensee plans to use as the basis for label expansion after the potential approval of leronlimab (PRO140) for HIV patients as a combination therapy with HAART.  The longer half-life of leronlimab may help to reduce the number of non-responders in the first ten weeks of monotherapy, if the treatment overlaps with existing regimen of leronlimab for four weeks before initiating monotherapy.  Under the current trial protocol, patients have 7 days of overlap with their HAART regimen and leronlimab before initiating monotherapy.

The U.S. Food and Drug Administration (FDA) has granted a “Fast Track” designation to leronlimab (PRO 140) as a combination therapy with HAART for HIV-infected patients.  Leronlimab (PRO 140) is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that appears to play multiple roles with implications in HIV infection, tumor metastases and immune signaling.  Leronlimab (PRO 140) has successfully completed nine Phase 1/2/3 clinical trials in over 700 people, including a successful pivotal Phase 3 trial in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients.

Field of use is to treat human immunodeficiency virus (“HIV”) patients with multiple resistance to current standard of care, COVID-19 patients, and metastatic Triple Negative Breast Cancer (“mTNBC”), among other indications.

IPSCIO Record ID: 56027

License Grant
The Company acquired the rights to the HIV viral-entry inhibitor drug candidate PRO 140, a humanized anti-CCR5 monoclonal antibody, as well as certain other related assets, including the existing inventory of bulk PRO 140 drug product, intellectual property, certain related licenses and sublicenses, and U.S. Food and Drug administration regulatory filings.
License Property
PRO 140 belongs to a class of HIV therapies known as entry inhibitors. These therapies block HIV from entering into and infecting certain cells. We believe that monoclonal antibodies are a new emerging class of therapeutics for the treatment of HIV. Seven clinical trials demonstrating safety and efficacy for PRO 140 have been completed.
Field of Use
The rights granted apply to the drug industry.

IPSCIO Record ID: 332224

License Grant
Licensor of Israel grants the exclusive right and license, including the right, subject to the Consent Agreement, to sublicense, under the Licensor Technology and Trademarks to Obtain Regulatory Approval, make, have made, use, promote, market, sell, have sold, offer to sell, import or export Products in the Territory.

Licensor grants an exclusive license under its entire right, title and interest in and to the Licensor Trademarks, if any, to use and display the Licensor Trademarks in connection with the Commercialization of Product within the Territory.

This agreement includes a non-exclusive grant back from Licensee to Licensor.

License Property
The trademark is HEPEX.

The patents include Human Monoclonal Antibody Against Hepatitis. B Surface Antigen {HBVSAG), and, Treatment of hepatitis B virus infection with human  monoclonal antibodies.

Additional HBV Products shall mean any and all compounds, products, methods or systems, other than a Product or a Directly Competitive Product, in any formulation for the treatment or prevention of Hepatitis 8, that is Controlled by Licensor as of the Effective Date or at any time during the term of this Agreement.

HB/g shall mean the immunoglobulin product containing polyclonal antibodies (derived from human plasma) to hepatitis B surface antigen, and occasionally referred to as HBlg.

HBV Antibody shall mean any and all human or humanized monoclonal immunoglobulins, including intact immunoglobulin molecules and any portion or fragment of an immunoglobulin molecule, such as those portions or fragments commonly known as Fab, Fab, F(ab)2 and F(v), that is directed to and binds to the Hepatitis B virus or any portion of the Hepatitis 8 virus.

HepeX-8 shall mean, without regard to the actual trade name used, any Product containing the human monoclonal antibody [17;1.41., as referred to and described in ECACC Accession No; 96()521.69], and the human monoclonal antibody [19.79.s,; as referred to and described in ECACC Accession No. 96052168], and no other antibodies or fragments of other antibodies.

Field of Use
The field is for use against Hepatitis B.

IPSCIO Record ID: 256253

License Grant
With this agreement, the French Licensee will receive an exclusive worldwide license to develop, manufacture and commercialize MM-121. Licensor will retain potential co-promotion rights in the United States.

Licensor grants the French Licensee an exclusive right and license, with the right to grant sub licenses, under Licensed Technology and Licensed Patent Rights, including Licensors rights to Joint Technology and Joint Patent Rights, to research, have researched, develop, have developed, make, have made, use, offer for sale, sell, have sold, import and export Collaboration Compounds and Licensed Products in the Field in the Territory.

This agreement includes a non-exclusive grant-back from Licensee to Licensor.

License Property
Licensor has rights to a monoclonal antibody, known as MM-121, with binding affinity to the ErbB3 protein.
MM-121 is a monoclonal antibody designed to block signaling of the ErbB3 receptor, a member of the epidermal growth factor (EGF) receptor family.  

The Collaboration Compound means MM121, or, any antibody fragment of MM-121, including any Fab, F(ab)2, Fv, and scFv fragments, or the primary molecular target of which is ErbB3.  ErbB3, also known as HER3, is a transmembrane receptor belonging to the epidermal growth factor (EGF) receptor family.

MM-121 is currently in Phase 1 clinical testing.

Licensed Technology means the Diagnostic Technology and the Therapeutic Technology.

Field of Use
Field means all human and veterinary fields of use, including therapeutic, prophylactic and diagnostic uses in all possible indications.

MM-121 a genetically engineered antibody designed to block a receptor on cells known as ErbB3. That’s thought to be an important new target for cancer drugs, because it’s a member of the epidermal growth factor receptor family of proteins, which are known to amplify cell proliferation that can give rise to out-of-control tumors.

The ErbB3 receptor is a novel target known to be a key mediator of signaling in the ErbB pathway (also known as the EGFR or HER pathway) – a signaling network that impacts a broad array of cancers. By targeting ErbB3, MM-121 is believed to have a broad application across cancer as both a monotherapy and in combination with other therapeutics.

IPSCIO Record ID: 28616

License Grant
The Licensor grants to the Licensee an exclusive worldwide commercial license under the Patent Rights to make and have made, to use and have used, to sell and have sold the Licensed Products, and to practice the Licensed Practices, for the life of the Patent Rights in all fields of use.
License Property
Patent applications relate to all uses of anti-CD4 802-2 and CD4 inhibitor technology.

United States Patent Application 07/977,692
United States Patent 5,589,458
PCT/US93/10999
United States Patent Application 5,958,882
United States Patent Application 5,846,933

Field of Use
The Licensee are developing a series of rationally-designed, small molecule/peptidomimetic inhibitors of the T-cell CD4 co-receptor. The CD4 co-receptor is central to a number of autoimmune disorders such as MS. Our anti-CD4 molecules are designed to selectively block the dimerization and oligomerization of adjacent CD4 receptors via the D1 domains of such receptors. CD4 dimerization is believed to be necessary for the proper formation of the immunological synapse between antigen presenting cells (APCs) and T-cells, which results in the achievement of the critical threshold signaling required for CD4 T-Cell activation.

The lead anti-CD4 molecule, 802-2 (cnsnqic-cylic), has demonstrated efficacy in a number of animal models of MS and other autoimmune disease models, and it is currently being evaluated in a phase I/II clinical trial for the prevention of severe graft-vs.-host disease. Anti-CD4 802-2 may represent the first clinical stage, non-antibody-based molecule capable of inducing immune tolerance for a variety of CD4-mediated autoimmune diseases.

IPSCIO Record ID: 365329

License Grant
This amendment, included with this agreement, updates the financial terms, including the royalty rates.

By the original agreement, University grants to an exclusive, world-wide right and license, with the right to grant sublicenses, to make, have made, use, import, sell and offer for sale University Licensed Products.

This license grant is exclusive with respect to Universitys rights, except that University may use and permit other nonprofit organizations to use the University Patent Rights for educational and research purposes and not for sale or offer of sale.

License Property
The University controls certain intellectual property developed related to pathogenic viral proteins which control host cell functions.
Field of Use
Licensee is a biopharmaceutical company engaged in the discovery and development of drugs and DNA vaccines for the treatment of infectious diseases, including the HIV and hepatitis C viruses, as well as cancer and inflammatory diseases.

IPSCIO Record ID: 139546

License Grant
The Canadian Company reacquired the 50% interest in the Antibody 1F7 acquired by Licensor.
License Property
The monoclonal antibody 1F7 has several important effects on both humoral (antibody-mediated) and cellular immunity mechanisms  that make it an ideal candidate for an HIV therapy.  The anti-idiotypic antibody 1F7 selectively inhibits cytotoxic T-cells activated in HIV-1 infection.  Immunol Cell Biol 78(1), 20-7.
Field of Use
This agreement pertains to the drug industry related to its use as a therapeutic for the prevention and treatment of HIV infection.

IPSCIO Record ID: 362516

License Grant
The University grants to an exclusive, world-wide right and license, with the right to grant sublicenses, to make, have made, use, import, sell and offer for sale University Licensed Products.

This license grant is exclusive with respect to Universitys rights, except that University may use and permit other nonprofit organizations to use the University Patent Rights for educational and research purposes and not for sale or offer of sale.

License Property
The University controls certain intellectual property developed related to pathogenic viral proteins which control host cell functions.
Field of Use
Licensee is a biopharmaceutical company engaged in the discovery and development of drugs and DNA vaccines for the treatment of infectious diseases, including the HIV and hepatitis C viruses, as well as cancer and inflammatory diseases.

IPSCIO Record ID: 383584

License Grant
Licensor grants a worldwide exclusive right and license under Know-how, with the right to sublicense others, to make, have made, use, sell, offer for sale and import Licensed Products.

Licensor grants an exclusive license under Patent Rights, with respect to Licensors fifty percent ownership interest in such Patent Rights, with the right to sublicense others, to make, have made, use, sell, offer for sale and import Licensed Products in all jurisdictions outside the United States.

License Property
Licensed Products shall mean Erbitux®, and matuzumab  as well as all derivatives, analogs, fragments, improvements, conjugates and bioequivalents of any of the foregoing.

Erbitux® shall mean cetuximab, and marketed as Erbitux®.

ERBITUX (cetuximab) is an epidermal growth factor receptor (EGFR) inhibitor. EGFR is a receptor found on both normal and tumor cells that is important for cell growth.

The patent is titled Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same.

Field of Use
Erbitux ( cetuximab) is a cancer medicine that interferes with the growth and spread of cancer cells in the body.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.